TWI721959B - 治療急性骨髓性白血病之抗ｃｄ３８抗體 - Google Patents

治療急性骨髓性白血病之抗ｃｄ３８抗體 Download PDF

Info

Publication number
TWI721959B
TWI721959B TW104140257A TW104140257A TWI721959B TW I721959 B TWI721959 B TW I721959B TW 104140257 A TW104140257 A TW 104140257A TW 104140257 A TW104140257 A TW 104140257A TW I721959 B TWI721959 B TW I721959B
Authority
TW
Taiwan
Prior art keywords
antibody
aml
seq
individual
use according
Prior art date
Application number
TW104140257A
Other languages
English (en)
Chinese (zh)
Other versions
TW201632201A (zh
Inventor
帕盧 多希
格溫 達內德斯諾耶斯
賽德里克 多斯桑托斯
艾美 塞瑟
曉川 尚
Original Assignee
美商健生生物科技公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商健生生物科技公司 filed Critical 美商健生生物科技公司
Publication of TW201632201A publication Critical patent/TW201632201A/zh
Application granted granted Critical
Publication of TWI721959B publication Critical patent/TWI721959B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N5/1027—Interstitial radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1042—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy with spatial modulation of the radiation beam within the treatment head
    • A61N5/1045—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy with spatial modulation of the radiation beam within the treatment head using a multi-leaf collimator, e.g. for intensity modulated radiation therapy or IMRT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1077—Beam delivery systems
    • A61N5/1084—Beam delivery systems for delivering multiple intersecting beams at the same time, e.g. gamma knives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001126—CD38 not IgG
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW104140257A 2014-12-04 2015-12-02 治療急性骨髓性白血病之抗ｃｄ３８抗體 TWI721959B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462087442P 2014-12-04 2014-12-04
US62/087,442 2014-12-04

Publications (2)

Publication Number Publication Date
TW201632201A TW201632201A (zh) 2016-09-16
TWI721959B true TWI721959B (zh) 2021-03-21

Family

ID=56092366

Family Applications (2)

Application Number Title Priority Date Filing Date
TW104140257A TWI721959B (zh) 2014-12-04 2015-12-02 治療急性骨髓性白血病之抗ｃｄ３８抗體
TW110104368A TWI775309B (zh) 2014-12-04 2015-12-02 治療急性骨髓性白血病之抗ｃｄ３８抗體

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW110104368A TWI775309B (zh) 2014-12-04 2015-12-02 治療急性骨髓性白血病之抗ｃｄ３８抗體

Country Status (26)

Country Link
US (2) US10793630B2 (https=)
EP (1) EP3227338A4 (https=)
JP (2) JP6802791B2 (https=)
KR (1) KR102597989B1 (https=)
CN (1) CN107406506A (https=)
AR (1) AR102921A1 (https=)
AU (2) AU2015358615B2 (https=)
BR (1) BR112017011749A2 (https=)
CA (1) CA2969717A1 (https=)
CL (1) CL2017001382A1 (https=)
DO (1) DOP2017000150A (https=)
EA (2) EA202092609A1 (https=)
EC (1) ECSP17042921A (https=)
HK (1) HK1247221A1 (https=)
IL (2) IL307913A (https=)
JO (1) JO3748B1 (https=)
MX (1) MX2017007208A (https=)
NI (1) NI201700071A (https=)
PE (1) PE20171094A1 (https=)
PH (1) PH12017501042A1 (https=)
SG (1) SG11201704390PA (https=)
TW (2) TWI721959B (https=)
UA (1) UA123697C2 (https=)
UY (1) UY36419A (https=)
WO (1) WO2016089960A1 (https=)
ZA (1) ZA202307128B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5225069B2 (ja) * 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
SMT202000031T1 (it) 2010-06-09 2020-03-13 Genmab As Anticorpi contro cd38 umano
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
PH12017500442B1 (en) 2014-09-09 2023-05-24 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
CN107406506A (zh) 2014-12-04 2017-11-28 詹森生物科技公司 用于治疗急性髓系白血病的抗cd38抗体
EA201792546A1 (ru) 2015-05-20 2018-04-30 Янссен Байотек, Инк. Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
IL256242B2 (en) 2015-06-22 2024-09-01 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CA3004152C (en) 2015-11-03 2024-04-16 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
WO2019109095A1 (en) * 2017-12-01 2019-06-06 Beth Israel Deaconess Medical Center, Inc. Arsenic trioxide and retinoic acid compounds for treatment of idh2-associated disorders
MX2021000307A (es) * 2018-07-11 2021-09-08 Momenta Pharmaceuticals Inc Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc dirigidos a cd38 diseñados por ingeniería genética.
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
CN109265551B (zh) * 2018-09-25 2020-09-15 华东师范大学 Cd38抗体、嵌合抗原受体和药物
GB201916150D0 (en) * 2019-11-06 2019-12-18 Univ Of Ireland Galway Treatment of multiple myeloma
MX2022007208A (es) * 2019-12-13 2022-09-21 Janssen Pharmaceuticals Inc Metodos y dispositivos para suministrar agentes terapeuticos liquidos en tumores solidos.
CN116670285A (zh) * 2020-06-23 2023-08-29 江苏康缘药业股份有限公司 抗cd38抗体及其用途
JP2023541457A (ja) 2020-09-14 2023-10-02 ブイオーアール バイオファーマ インコーポレーテッド Ｃｄ３８修飾のための化合物および方法
WO2022152823A1 (en) 2021-01-14 2022-07-21 Morphosys Ag Anti-cd38 antibodies and their uses
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
JP7767722B2 (ja) 2021-03-16 2025-11-12 東ソー株式会社 ラミネート用延伸ポリエチレンフィルム
JP2024546152A (ja) * 2021-12-16 2024-12-17 上海宝済薬業股▲ふん▼有限公司 免疫グロブリン分解酵素による切断に対抗するＦｃ変異体

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829673B2 (en) * 2005-03-23 2010-11-09 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
US8088896B2 (en) * 2005-10-12 2012-01-03 Morphosys Ag Generation and profiling of fully human gold-derived therapeutic antibodies specific for human CD38
US8153765B2 (en) * 2006-10-19 2012-04-10 Sanof Aventis Anti-CD38 antibodies for the treatment of cancer
US20120244110A1 (en) * 2011-03-23 2012-09-27 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
US20120295864A1 (en) * 2010-11-29 2012-11-22 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia

Family Cites Families (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
WO1989008114A1 (en) 1988-02-25 1989-09-08 The General Hospital Corporation Rapid immunoselection cloning method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH06504186A (ja) 1990-07-13 1994-05-19 ザ ジェネラル ホスピタル コーポレイション Ｃｄ５３細胞表面抗原とその使用
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
AU6123894A (en) 1993-01-29 1994-08-15 Board Of Trustees Of The Leland Stanford Junior University Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO1998016245A1 (fr) 1996-10-15 1998-04-23 Shionogi & Co., Ltd. Procede de determination d'un auto-anticorps
DK0932417T3 (da) 1996-10-17 2003-04-14 Immunomedics Inc Non-antigent toxinkonjugat og fusionsprotein af internaliserende receptorsystem
WO2000006194A2 (en) 1997-02-05 2000-02-10 Biotransplant, Inc. Depletion of cells responsible for antibody-mediated graft rejection
JP3835827B2 (ja) 1997-05-02 2006-10-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ リプレゼンティッド バイ ザ セクレタリーオブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 悪性細胞に対する、ｏｎｃタンパク質を含む、免疫毒素
WO1999062526A2 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
KR100737090B1 (ko) 2000-02-15 2007-07-06 아스텔라스세이야쿠 가부시키가이샤 축합 이미다졸륨 유도체
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
JP2003535908A (ja) 2000-06-22 2003-12-02 アイデック ファーマスーティカルズ コーポレイション 二重特異性融合タンパク及び標的細胞を殺傷するエフェクター細胞を増強するための使用方法
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
CA2424643A1 (en) 2000-10-17 2002-04-25 Trudeau Institute, Inc. Cd38 modulated chemotaxis
US20070042436A1 (en) 2000-10-17 2007-02-22 Lund Frances E CD38 modulated chemotaxis
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US20040166490A1 (en) 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
DE60317677T2 (de) 2002-06-13 2008-10-30 Crucell Holland B.V. Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
ZA200503075B (en) * 2002-11-07 2006-09-27 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
NZ542873A (en) 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
MXPA05011078A (es) 2003-04-15 2006-01-24 Astellas Pharma Inc Bromuro y sus cristales.
UA101945C2 (uk) 2003-05-30 2013-05-27 Дженентек, Инк. Лікування злоякісного новоутворення за допомогою бевацизумабу
JP4794301B2 (ja) 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
CA2542840A1 (en) 2003-10-22 2005-05-12 University Of Rochester Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis
KR101128777B1 (ko) 2003-11-04 2012-04-13 조마 테크놀로지 리미티드 다발성 골수종을 치료하기 위한 길항제 항-ｃｄ４０단클론성 항체의 용도
WO2005063819A2 (en) 2003-12-23 2005-07-14 Crucell Holland B.V. Human binding molecule against cd1a
AU2005235811B2 (en) * 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
KR20140066259A (ko) 2004-02-06 2014-05-30 모르포시스 아게 항-ｃｄ３８ 인간 항체 및 그의 용도
US20050266008A1 (en) * 2004-03-29 2005-12-01 Medarex, Inc. Human anti-IRTA-5 antibodies
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
US20090304687A1 (en) 2005-12-09 2009-12-10 Seattle Genetics , Inc. Methods of using cd40 binding agents
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
DK2049109T3 (en) * 2006-08-02 2016-01-11 Sunesis Pharmaceuticals Inc Combined use of (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid and cytarabine (Ara-C) for the treatment of leukemia
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
WO2008037257A2 (en) 2006-09-26 2008-04-03 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US7618992B2 (en) 2006-12-29 2009-11-17 Astellas Pharma Inc. Method of treating cancer by co-administration of anticancer agents
EP2136839A4 (en) 2007-03-22 2010-04-07 Imclone Llc STABLE ANTIBODY FORMULATIONS
ES2593484T3 (es) 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
CA2682292A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
WO2008150530A2 (en) 2007-06-01 2008-12-11 Biogen Idec Ma Inc. Cripto binding molecules
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
CA2733676A1 (en) * 2007-08-10 2009-02-19 British Columbia Cancer Agency Branch Microrna compositions and methods for the treatment of myelogenous leukemia
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
MX2010005099A (es) 2007-11-09 2010-05-27 Novartis Ag Usos de anticuerpos anti-cd40.
US8440199B2 (en) 2007-12-12 2013-05-14 Imperial Innovations Limited Methods for mobilizing mesenchymal stem cells in a patient
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
AU2009221916A1 (en) 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
SI4269578T1 (sl) 2008-03-06 2024-07-31 Halozyme, Inc. Sestava topne hialuronidaze
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
RU2589704C2 (ru) 2008-03-25 2016-07-10 Роше Гликарт Аг Применение антитела к cd20 типа ii, обладающего повышенной антитело-обусловленной клеточнозависимой цитотоксичностью (adcc), в сочетании с циклофосфамидом, винкристином и доксорубицином для лечения неходжкинских лимфом
KR20130116386A (ko) 2008-04-14 2013-10-23 할로자임, 아이엔씨 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
KR101695327B1 (ko) 2008-11-07 2017-01-11 암젠 리서치 (뮌헨) 게엠베하 급성 림프구성 백혈병의 치료방법
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
SMT202000092T1 (it) * 2009-05-14 2020-05-08 Ambit Biosciences Corp Formulazione essiccata a spruzzo o liofilizzata di ac220
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
HUE028832T2 (en) 2009-09-17 2017-01-30 Baxalta Inc Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation
JP5898082B2 (ja) 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
NZ602685A (en) 2010-03-01 2014-10-31 Cytodyn Inc Concentrated protein formulations and uses thereof
GB201003701D0 (en) 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
US20130137134A1 (en) 2010-03-29 2013-05-30 Ben Gurion University Of The Negev Research And Development Authority Method and system for detecting and monitoring hematological cancer
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
SMT202000031T1 (it) * 2010-06-09 2020-03-13 Genmab As Anticorpi contro cd38 umano
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
DK2621531T3 (en) 2010-09-27 2017-02-27 Morphosys Ag ANTI-CD38 ANTIBODY AND LENALIDOMIDE OR BORTEZOMIB FOR TREATMENT OF MULTIPLE MYELOM AND NHL
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
CL2013001944A1 (es) 2010-12-30 2014-09-12 Takeda Pharmaceutical Anticuerpo aislado que se une especificamente a cd38 humana y cd38 de cinomolgo; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar una enfermedad autoinmune.
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
AR085934A1 (es) 2011-04-08 2013-11-06 Ab Science Tratamiento de mieloma multiple con masitinib
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
EP2561868A1 (en) 2011-08-24 2013-02-27 Anton Bernhard Van Oosten Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field
US20140309183A1 (en) 2011-08-24 2014-10-16 David Kerr Low-Dose Combination Chemotherapy
EP3559049B1 (en) * 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
WO2013083140A1 (en) 2011-12-07 2013-06-13 N.V. Nutricia Beta-lactoglobulin peptides for treating cow's milk protein allergy
WO2013102144A2 (en) 2011-12-30 2013-07-04 Halozyme, Inc. Ph20 polypeptede variants, formulations and uses thereof
WO2013116307A1 (en) * 2012-01-30 2013-08-08 Mount Sinai School Of Medicine Method for programming differentiated cells into hematopoietic stem cells
JP2015509526A (ja) 2012-03-07 2015-03-30 カディラ ヘルスケア リミティド 医薬製剤
CN108686203A (zh) 2012-04-04 2018-10-23 哈洛齐梅公司 使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
MX368288B (es) 2012-09-25 2019-09-27 Morphosys Ag Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple.
DK2914302T3 (en) 2012-11-05 2017-04-10 Morphosys Ag RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT
UA118255C2 (uk) 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
CN105188749B (zh) 2012-12-21 2017-12-19 西雅图基因公司 抗ntb‑a抗体及相关组合物和方法
WO2014142220A1 (ja) 2013-03-13 2014-09-18 アステラス製薬株式会社 抗腫瘍剤
US20140271644A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Combination/adjuvant therapy for wt-1-positive disease
BR112015027313A2 (pt) 2013-04-29 2017-09-26 Teva Pharmaceuticals Australia Pty Ltd anticorpos anti-cd38 e fusões ao interferon alfa-2b atenuado
US20140356318A1 (en) 2013-05-28 2014-12-04 Israel Barken Adoptive cell therapy with specific regulatory lymphocytes
EP3021866A4 (en) 2013-07-15 2017-02-22 The Board of Trustees of the Leland Stanford Junior University Medical uses of cd38 agonists
US20150118251A1 (en) 2013-10-31 2015-04-30 Sanofi Specific anti-cd38 antibodies for treating human cancers
EP3066125A2 (en) 2013-11-06 2016-09-14 Boehringer Ingelheim International GmbH Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents
WO2015121454A1 (en) 2014-02-14 2015-08-20 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
EP3154581B1 (en) * 2014-06-16 2019-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells
WO2015195555A1 (en) 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
US9499514B2 (en) * 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
PH12017500442B1 (en) 2014-09-09 2023-05-24 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
CN107406506A (zh) 2014-12-04 2017-11-28 詹森生物科技公司 用于治疗急性髓系白血病的抗cd38抗体
MA41555A (fr) 2015-02-17 2017-12-26 Millennium Pharm Inc Polythérapie pour le traitement du cancer
EA201792546A1 (ru) 2015-05-20 2018-04-30 Янссен Байотек, Инк. Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
MX2017015937A (es) 2015-06-08 2018-12-11 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
IL256242B2 (en) 2015-06-22 2024-09-01 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
EA037548B1 (ru) 2015-06-24 2021-04-12 Янссен Байотек, Инк. Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
CN107921050A (zh) 2015-06-29 2018-04-17 阿布拉科斯生物科学有限公司 使用纳米颗粒mtor抑制剂联合疗法治疗血液学恶性肿瘤的方法
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CA3004152C (en) 2015-11-03 2024-04-16 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
US20170121417A1 (en) 2015-11-03 2017-05-04 Janssen Biotech, Inc. Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
US20180117150A1 (en) 2016-11-01 2018-05-03 Janssen Biotech, Inc. Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide
KR20200005662A (ko) 2017-05-18 2020-01-15 테사로, 인코포레이티드 암을 치료하기 위한 조합 요법
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
KR20250117714A (ko) 2018-03-28 2025-08-05 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투약
US20190298827A1 (en) 2018-04-03 2019-10-03 Janssen Biotech, Inc. Methods of Treating Multiple Myeloma
UA130542C2 (uk) 2018-05-16 2026-03-18 Янссен Байотек, Інк. Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта
KR20210077725A (ko) 2018-10-17 2021-06-25 얀센 바이오테크 인코포레이티드 항-cd38 항체의 피하 투여를 제공하는 방법
EA202191352A1 (ru) 2018-11-13 2021-08-11 Янссен Байотек, Инк. Контроль содержания микроэлементов-металлов во время продукции антител к cd38
WO2020170211A1 (en) 2019-02-22 2020-08-27 Janssen Biotech, Inc. Methods of treating newly diagnosed multiple myeloma with a combination of an antibody that specifically binds cd38, lenalidomide and dexamethasone
WO2020194243A1 (en) 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with lenalidomide and dexamethasone
WO2020194244A1 (en) 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with bortezomib and dexamethasone
WO2020194242A1 (en) 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with pomalidomide and dexamethasone
US20200308297A1 (en) 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses
WO2020194245A1 (en) 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with bortezomib, melphalan and prednisone
US20200397896A1 (en) 2019-04-19 2020-12-24 Janssen Biotech, Inc. Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
US20200405854A1 (en) 2019-04-19 2020-12-31 Janssen Biotech, Inc. Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
US20200392242A1 (en) 2019-04-19 2020-12-17 Janssen Biotech, Inc. Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
CN114286681B (zh) 2019-06-04 2024-08-16 上海科技大学 Nad+和/或nad+抑制剂和/或nad+激动剂的用途及其联合制剂
US20220275101A1 (en) 2021-02-09 2022-09-01 Janssen Biotech, Inc. Use of Approved Anti-CD38 Antibody Drug Product to Treat Light Chain Amyloidosis
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829673B2 (en) * 2005-03-23 2010-11-09 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
US8088896B2 (en) * 2005-10-12 2012-01-03 Morphosys Ag Generation and profiling of fully human gold-derived therapeutic antibodies specific for human CD38
US8153765B2 (en) * 2006-10-19 2012-04-10 Sanof Aventis Anti-CD38 antibodies for the treatment of cancer
US20120295864A1 (en) * 2010-11-29 2012-11-22 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US20120244110A1 (en) * 2011-03-23 2012-09-27 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3

Also Published As

Publication number Publication date
JO3748B1 (ar) 2021-01-31
EP3227338A4 (en) 2018-05-16
ZA202307128B (en) 2024-10-30
AU2015358615B2 (en) 2021-08-05
US20160222106A1 (en) 2016-08-04
US10793630B2 (en) 2020-10-06
IL252568A0 (en) 2017-07-31
DOP2017000150A (es) 2017-12-15
EA037084B9 (ru) 2021-08-05
JP2021042232A (ja) 2021-03-18
CA2969717A1 (en) 2016-06-09
HK1247221A1 (zh) 2018-09-21
WO2016089960A1 (en) 2016-06-09
JP6802791B2 (ja) 2020-12-23
NZ732753A (en) 2024-08-30
US20210047401A1 (en) 2021-02-18
MX2017007208A (es) 2018-01-30
BR112017011749A2 (pt) 2018-05-15
EA037084B1 (ru) 2021-02-04
PH12017501042A1 (en) 2017-11-27
CL2017001382A1 (es) 2018-01-05
TW201632201A (zh) 2016-09-16
PE20171094A1 (es) 2017-08-07
NI201700071A (es) 2017-12-22
TW202144413A (zh) 2021-12-01
TWI775309B (zh) 2022-08-21
AR102921A1 (es) 2017-04-05
EP3227338A1 (en) 2017-10-11
ECSP17042921A (es) 2017-11-30
EA202092609A1 (ru) 2021-10-29
US12286474B2 (en) 2025-04-29
KR102597989B1 (ko) 2023-11-02
UA123697C2 (uk) 2021-05-19
UY36419A (es) 2016-06-30
CN107406506A (zh) 2017-11-28
JP2018502834A (ja) 2018-02-01
KR20170088969A (ko) 2017-08-02
IL307913A (en) 2023-12-01
AU2021218021A1 (en) 2021-09-09
AU2021218021B2 (en) 2024-10-24
SG11201704390PA (en) 2017-06-29
AU2015358615A1 (en) 2017-06-15
EA201791208A1 (ru) 2017-10-31

Similar Documents

Publication Publication Date Title
US12286474B2 (en) Anti-CD38 antibodies for treatment of acute myeloid leukemia
US11713355B2 (en) Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
AU2015315396B2 (en) Combination therapies with anti-CD38 antibodies
EA050043B1 (ru) Антитела к cd38 для лечения острого миелолейкоза
NZ723538B2 (en) Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia